NPJ Parkinson's Disease最新文献_第2页

Gardenia-derived extracellular vesicles exert therapeutic effects on dopaminergic neuron apoptosis-mediated Parkinson’s disease 栀子源性细胞外囊泡对多巴胺能神经元凋亡介导的帕金森病的治疗作用

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-01044-6

Wen Chen, Haobo Wang, Xiang Ye, Xingkai Hao, Fujie Yan, Jian Wu, Danyang Li, Yan Wang, Lizhou Xu

{"title":"Gardenia-derived extracellular vesicles exert therapeutic effects on dopaminergic neuron apoptosis-mediated Parkinson’s disease","authors":"Wen Chen, Haobo Wang, Xiang Ye, Xingkai Hao, Fujie Yan, Jian Wu, Danyang Li, Yan Wang, Lizhou Xu","doi":"10.1038/s41531-025-01044-6","DOIUrl":"https://doi.org/10.1038/s41531-025-01044-6","url":null,"abstract":"Plant-derived extracellular vesicles (EVs) show health benefits. Gardenia jasminoides Ellis, known for its neuroprotective properties, lacks therapeutic investigation on gardenia-derived extracellular vesicles (GDEVs). This study investigated the value of GDEVs in Parkinson’s disease (PD) using rotenone (Rot)-induced Parkinsonism models in dopaminergic PC12 neuron cells and Caenorhabditis elegans. PD features apoptosis in dopaminergic neurons, while GDEVs alleviate PD by mitigating mitochondrial-mediated apoptosis. Specifically, GDEVs improve Rot-induced mitochondrial dysfunction to reduce cytochrome C release and apoptosis. Consequently, GDEVs reduce the risk of PD by lowering α-synuclein levels and regulating dopamine release. RNA sequencing and subsequent studies showed that GDEVs reduce p38 MAPK and p53 phosphorylation levels, and increase the Bcl-2/Bax ratio to prevent apoptosis in PC12 cells. In Caenorhabditis elegans, we verified that GDEVs reduce PD progression by increasing dopaminergic neurons using BZ555 mutants, and enhance dopamine release and motility. This study highlights the therapeutic potential of GDEVs in preventing neurodegenerative diseases.<figure></figure>","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"19 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort 在一项大型合并事件队列中，β -肾上腺素能受体药物与帕金森病进展里程碑

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-01014-y

Ruwani S. Wijeyekoon, Marta Camacho, David Bäckström, Lars Forsgren, Rachael A. Lawson, Alison J. Yarnall, Angus D. Macleod, Carl E. Counsell, Ole-Bjørn Tysnes, Guido Alves, Jodi Maple-Grødem, Roger A. Barker, Caroline H. Williams-Gray

{"title":"Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort","authors":"Ruwani S. Wijeyekoon, Marta Camacho, David Bäckström, Lars Forsgren, Rachael A. Lawson, Alison J. Yarnall, Angus D. Macleod, Carl E. Counsell, Ole-Bjørn Tysnes, Guido Alves, Jodi Maple-Grødem, Roger A. Barker, Caroline H. Williams-Gray","doi":"10.1038/s41531-025-01014-y","DOIUrl":"https://doi.org/10.1038/s41531-025-01014-y","url":null,"abstract":"Beta-adrenoceptor-blockers and agonists have been associated with an increased and decreased risk of Parkinson’s disease (PD), respectively. We aimed to investigate whether these medications are linked to clinical heterogeneity and progression in PD. Longitudinal data from the Parkinson’s Incident Cohorts Collaboration (n = 1107) were analysed. Baseline clinical status and progression to Hoehn & Yahr stage 3 (H&Y3) or dementia were compared in beta-blocker or beta-agonist users versus non-users of each drug. Baseline motor and cognitive variables were similar in beta-blocker users (n = 195) versus non-users and beta-agonist users (n = 68) versus non-users, following adjustment for relevant confounders. Beta-blocker users (n = 156) progressed faster to H&Y3 (p = 0.002), accounting for relevant confounders (Hazard Ratio (HR) = 1.538; p = 0.011), while beta-agonist users (n = 54) progressed similarly to non-users. Neither drug was associated with progression to dementia. These findings support the possibility that beta-adrenoceptor drugs may have potential in modifying aspects of PD progression. Further investigation is essential to identify any causative component in the relationship.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"5 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores 帕金森氏病风险的祖先多样性洞察：多基因风险评分的比较评估

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-00967-4

Paula Saffie-Awad, Spencer M. Grant, Mary B. Makarious, Inas Elsayed, Arinola O. Sanyaolu, Peter Wild Crea, Artur F. Schumacher Schuh, Kristin S. Levine, Dan Vitale, Mathew J. Koretsky, Jeffrey Kim, Thiago Peixoto Leal, María Teresa Periñán, Sumit Dey, Alastair J. Noyce, Armando Reyes-Palomares, Noela Rodriguez-Losada, Jia Nee Foo, Wael Mohamed, Karl Heilbron, Lucy Norcliffe-Kaufmann, Mie Rizig, Njideka Okubadejo, Mike A. Nalls, Cornelis Blauwendraat, Andrew Singleton, Hampton Leonard, Ignacio F. Mata, Sara Bandres-Ciga

{"title":"Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scores","authors":"Paula Saffie-Awad, Spencer M. Grant, Mary B. Makarious, Inas Elsayed, Arinola O. Sanyaolu, Peter Wild Crea, Artur F. Schumacher Schuh, Kristin S. Levine, Dan Vitale, Mathew J. Koretsky, Jeffrey Kim, Thiago Peixoto Leal, María Teresa Periñán, Sumit Dey, Alastair J. Noyce, Armando Reyes-Palomares, Noela Rodriguez-Losada, Jia Nee Foo, Wael Mohamed, Karl Heilbron, Lucy Norcliffe-Kaufmann, Mie Rizig, Njideka Okubadejo, Mike A. Nalls, Cornelis Blauwendraat, Andrew Singleton, Hampton Leonard, Ignacio F. Mata, Sara Bandres-Ciga","doi":"10.1038/s41531-025-00967-4","DOIUrl":"https://doi.org/10.1038/s41531-025-00967-4","url":null,"abstract":"Risk prediction models play a crucial role in advancing healthcare by enabling early detection and supporting personalized medicine. Nonetheless, polygenic risk scores (PRS) for Parkinson’s disease (PD) have not been extensively studied across diverse populations, contributing to health disparities. In this study, we constructed 105 PRS using individual-level data from seven ancestries and compared two different models. Model 1 was based on the cumulative effect of 90 known European PD risk variants, weighted by summary statistics from four independent ancestries (European, East Asian, Latino/Admixed American, and African/Admixed). Model 2 leveraged multi-ancestry summary statistics using a p-value thresholding approach to improve prediction across diverse populations. Our findings provide a comprehensive assessment of PRS performance across ancestries and highlight the limitations of a “one-size-fits-all” approach to genetic risk prediction. We observed variability in predictive performance between models, underscoring the need for larger sample sizes and ancestry-specific approaches to enhance accuracy. These results establish a foundation for future research aimed at improving generalizability in genetic risk prediction for PD.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"70 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder 孤立性快速眼动睡眠行为障碍的皮层宏观和微观结构变化

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-01058-0

Jèssica Pardo, Ignacio Roura, Victor Montal, Cristina Martín-Barceló, Javier Oltra, Anna Campabadal, Núria Bargalló, Mònica Serradell, Gerard Mayà, Angelica Montini, Carles Gaig, Claustre Pont-Sunyer, Juan Fortea, Alex Iranzo, Carme Junqué, Bàrbara Segura

{"title":"Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder","authors":"Jèssica Pardo, Ignacio Roura, Victor Montal, Cristina Martín-Barceló, Javier Oltra, Anna Campabadal, Núria Bargalló, Mònica Serradell, Gerard Mayà, Angelica Montini, Carles Gaig, Claustre Pont-Sunyer, Juan Fortea, Alex Iranzo, Carme Junqué, Bàrbara Segura","doi":"10.1038/s41531-025-01058-0","DOIUrl":"https://doi.org/10.1038/s41531-025-01058-0","url":null,"abstract":"Cortical mean diffusivity (cMD), a marker of cortical microstructural changes in neurodegenerative disorders, remains unexplored in isolated REM sleep behavior disorder (iRBD), a prodromal stage of Lewy body (LB) diseases. Its relationship with cortical thickness (CTh), clinical features, and neuropsychological performance is also unknown. We assessed cMD and CTh in thirty-six patients with iRBD at high risk of conversion and 29 healthy controls (HC), examining associations with clinical and cognitive measures. Effect sizes were calculated using Cohen’s d. Patients with iRBD showed increased cMD in rostral and caudal cortical regions compared to HC (d > 0.5). Cortical thinning was restricted to caudal areas. Higher cMD correlated with longer iRBD duration, later onset, MDS-UPDRS III, apathy, and poorer performance on Grooved Pegboard and Symbol-Digit Modality Tests. These findings suggest that cMD may be more sensitive than CTh and serve as a valuable imaging biomarker for detecting early cortical changes in prodromal LB diseases.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"28 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiparametric quantitative MRI uncovers putamen microstructural changes in Parkinson’s disease 多参数定量MRI揭示帕金森病壳核微结构变化

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-01020-0

Elior Drori, Lee Cohen, David Arkadir, Gilad Yahalom, Aviv A. Mezer

{"title":"Multiparametric quantitative MRI uncovers putamen microstructural changes in Parkinson’s disease","authors":"Elior Drori, Lee Cohen, David Arkadir, Gilad Yahalom, Aviv A. Mezer","doi":"10.1038/s41531-025-01020-0","DOIUrl":"https://doi.org/10.1038/s41531-025-01020-0","url":null,"abstract":"Parkinson’s disease (PD) is a progressive neurodegenerative disorder dominated by motor and non-motor dysfunction. Despite extensive research, in vivo characterization of PD-related brain microstructure remains a challenge, limiting diagnostic and therapeutic advances. The putamen, a subcortical region crucial for movement regulation, is prominently affected in early PD. Here, we collected multiparametric quantitative MRI (qMRI) data from PD patients and healthy controls, to investigate biophysical alterations in the putamen. Gradient analysis revealed significant spatial variation and interhemispheric asymmetries in biophysical properties – including relaxation rates (R1, R2, R2*), water fraction (WF), susceptibility, MTsat, and diffusion metrics (MD, FA) – along its anterior-posterior axis. PD patients showed altered gradients, particularly increased WF in the posterior putamen, suggesting tissue atrophy or neuroinflammation, and correlating with motor symptom laterality. Our findings highlight the posterior putamen as a PD pathology hotspot and demonstrate the potential of qMRI gradient analysis for detecting clinically relevant brain changes.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"20 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel technologies for REM sleep behavior disorder detection for home screening in Parkinson’s disease and related alpha-synucleinopathies 帕金森病及相关α -突触核蛋白病家庭筛查中快速眼动睡眠行为障碍检测的新技术

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-03 DOI: 10.1038/s41531-025-01032-w

Kaat Colman, An-Marie Schyvens, Ilse De Volder, Johan Verbraecken, Angelique Pijpers, Mineke Viaene, Wolfgang Oertel, Femke Dijkstra, David Crosiers

{"title":"Novel technologies for REM sleep behavior disorder detection for home screening in Parkinson’s disease and related alpha-synucleinopathies","authors":"Kaat Colman, An-Marie Schyvens, Ilse De Volder, Johan Verbraecken, Angelique Pijpers, Mineke Viaene, Wolfgang Oertel, Femke Dijkstra, David Crosiers","doi":"10.1038/s41531-025-01032-w","DOIUrl":"https://doi.org/10.1038/s41531-025-01032-w","url":null,"abstract":"Isolated REM sleep behavior disorder (iRBD) is a prodromal marker of Parkinson’s disease (PD) and related alpha-synucleinopathies. Identification of RBD is crucial for timely intervention and disease-modifying treatments. While video-polysomnography (vPSG) remains the diagnostic gold standard, its costly and resource-intensive nature limits its utility. This systematic review evaluates emerging non-PSG tools and modalities for home-based RBD detection. A systematic search of PubMed, Web of Science, and Cochrane Library identified 17 studies, categorized into actigraphy devices (n = 9), novel tools (n = 5), and emerging modalities (n = 3). Advances in actigraphy, through machine learning integration, have significantly improved RBD detection. Novel tools, including portable biopotential systems and temporary tattoo electrodes, show promise for home-based REM sleep without atonia monitoring, while contactless cameras demonstrate high sensitivity for dream-enacting behavior detection. Future studies for validation are needed, ensuring reliability and clinical applicability for large-scale screening efforts aimed at identifying individuals at risk for PD and related alpha-synucleinopathies.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"69 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder 脑电图α峰频率：孤立性快速眼动睡眠行为障碍的认知障碍严重程度标志

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-01 DOI: 10.1038/s41531-025-01059-z

Sophia Schopp, Jan de Zeeuw, Sophia Stotz, Martin Haberecht, Katy Sahra Weihrich, Michail Plotkin, Frederik Bes, Dieter Kunz

{"title":"EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder","authors":"Sophia Schopp, Jan de Zeeuw, Sophia Stotz, Martin Haberecht, Katy Sahra Weihrich, Michail Plotkin, Frederik Bes, Dieter Kunz","doi":"10.1038/s41531-025-01059-z","DOIUrl":"https://doi.org/10.1038/s41531-025-01059-z","url":null,"abstract":"Isolated REM sleep behavior disorder (iRBD) is a prodrome of α-synucleinopathies like Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). The best marker for prediction of lead time to phenoconversion is reduced striatal dopamine transporter (DaT)-binding, unavailable for most patients. This study investigated EEG alpha peak frequency (APF) slowing – an established marker of cognitive deterioration – as a severity marker in iRBD patients. In 320 patients clinically suspected of RBD 3-night-polysomnography was performed. After exclusion of 131 patients, mainly due to psychotropic medication, three groups were studied: Non-Syn – motor behavior unrelated to RBD (n = 34); iRBD (n = 122); RBD converted to overt α-synucleinopathies (PD = 19; DLB = 14). Data show in patients with iRBD significant correlations between APF, DaT-binding ratios and cognition. The strong correlation of APF < 8 Hz with caudate DaT-binding (r = 0.50–0.65) suggests, APF could be an easy-to-use severity marker for counseling patients on lead time until possible conversion to overt α-synucleinopathy especially in DLB.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"16 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning for Parkinson’s disease: a comprehensive review of datasets, algorithms, and challenges 帕金森病的机器学习：对数据集、算法和挑战的全面回顾

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-01 DOI: 10.1038/s41531-025-01025-9

Sahar Shokrpour, AmirMehdi MoghadamFarid, Sepideh Bazzaz Abkenar, Mostafa Haghi Kashani, Mohammad Akbari, Mostafa Sarvizadeh

{"title":"Machine learning for Parkinson’s disease: a comprehensive review of datasets, algorithms, and challenges","authors":"Sahar Shokrpour, AmirMehdi MoghadamFarid, Sepideh Bazzaz Abkenar, Mostafa Haghi Kashani, Mohammad Akbari, Mostafa Sarvizadeh","doi":"10.1038/s41531-025-01025-9","DOIUrl":"https://doi.org/10.1038/s41531-025-01025-9","url":null,"abstract":"Parkinson’s disease (PD) is a devastating neurological ailment affecting both mobility and cognitive function, posing considerable problems to the health of the elderly across the world. The absence of a conclusive treatment underscores the requirement to investigate cutting-edge diagnostic techniques to improve patient outcomes. Machine learning (ML) has the potential to revolutionize PD detection by applying large repositories of structured data to enhance diagnostic accuracy. 133 papers published between 2021 and April 2024 were reviewed using a systematic literature review (SLR) methodology, and subsequently classified into five categories: acoustic data, biomarkers, medical imaging, movement data, and multimodal datasets. This comprehensive analysis offers valuable insights into the applications of ML in PD diagnosis. Our SLR identifies the datasets and ML algorithms used for PD diagnosis, as well as their merits, limitations, and evaluation factors. We also discuss challenges, future directions, and outstanding issues.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"19 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144521158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient, target, device, and program selection for DBS in Parkinson's disease: advancing toward precision care. 帕金森病DBS的患者、靶标、设备和方案选择：向精准护理迈进。

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-01 DOI: 10.1038/s41531-025-01015-x

Aparna Wagle Shukla,Manuel Bange,Muthuraman Muthuraman

{"title":"Patient, target, device, and program selection for DBS in Parkinson's disease: advancing toward precision care.","authors":"Aparna Wagle Shukla,Manuel Bange,Muthuraman Muthuraman","doi":"10.1038/s41531-025-01015-x","DOIUrl":"https://doi.org/10.1038/s41531-025-01015-x","url":null,"abstract":"In Parkinson's disease (PD), several key factors influence patient selection for deep brain stimulation (DBS) as they directly affect long-term outcomes. A comprehensive interdisciplinary assessment is the first step to evaluating risks, benefits, and establishing appropriate goals. Patient-defined symptom priorities play a critical role in selecting the brain target for DBS. The entry of multiple manufacturers of hardware has spurred a rapid acceleration of technological progress. While innovations in programming such as sensing-based physiology-guided programming have introduced the concept of delivering an optimal or \"Goldilocks dose\", a precise, personalized therapy to address specific PD symptoms, image-guided programming acts like a \"GPS,\" enabling faster determination of dose parameters. Emerging tools such as adaptive and automated programming offer clinicians the potential to provide optimal, energy-efficient stimulation. This review, integrating both old and well-established knowledge and new insights, provides a comprehensive summary of the multidimensional aspects of patient selection, target-specific benefits, advancements in hardware technology, and innovative strategies that are either currently available or on the horizon for DBS programming.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"11 1","pages":"195"},"PeriodicalIF":8.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of two types of repetitive transcranial magnetic stimulation on brain network in Parkinson’s disease 两种重复经颅磁刺激对帕金森病脑网络的影响

IF 8.7 1区医学

NPJ Parkinson's Disease Pub Date : 2025-07-01 DOI: 10.1038/s41531-025-01054-4

Shuo Liu, Shuo Yang, Chen Wang, Jiarui Li, Lei Wang

{"title":"Effects of two types of repetitive transcranial magnetic stimulation on brain network in Parkinson’s disease","authors":"Shuo Liu, Shuo Yang, Chen Wang, Jiarui Li, Lei Wang","doi":"10.1038/s41531-025-01054-4","DOIUrl":"https://doi.org/10.1038/s41531-025-01054-4","url":null,"abstract":"Intermittent theta burst stimulation (iTBS) may have higher efficiency and stronger excitatory effects compared to conventional high-frequency repetitive transcranial magnetic stimulation (HF-rTMS). To evaluate the therapeutic effects of the two modalities, we compared the differences in spatiotemporal variability of electroencephalography (EEG) microstate-based brain networks between 51 PD patients and 21 healthy controls. The 51 PD patients were randomly assigned to either iTBS or 10Hz-rTMS groups to compare pre- and post-treatment clinical assessment results and spatiotemporal variability changes. Baseline measurements showed significant differences in spatiotemporal variability between PD patients and healthy controls, with certain brain regions demonstrating significant correlations between spatiotemporal variability and clinical assessment results. Both treatment groups exhibited significant improvements in all clinical outcomes compared to baseline. The iTBS group showed post-treatment changes involving more brain regions in spatiotemporal variability. This study demonstrates that compared to 10Hz-rTMS, iTBS can reduce treatment time while providing superior improvement in functional brain connectivity for PD patients.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"47 1","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0